Tumor location relative to the spleen is a prognostic factor in lymphoma patients: a demonstration from the REMARC trial
Published in Journal of Nuclear Medicine, 2024
This study introduces three PET/CT biomarkers—SpreadSpleen, Dspleen, and sDspleen—that quantify tumor spread relative to the spleen in DLBCL patients. These biomarkers predict progression-free and overall survival and improve the prognostic value of metrics like TMTV and age-adjusted IPI. Using AI-based spleen segmentation, the features are simple, interpretable, and potentially useful for clinical integration.
Recommended citation: Girum KB, Cottereau AS, Vercellino L, et al. Tumor location relative to the spleen is a prognostic factor in lymphoma patients: a demonstration from the REMARC trial. J Nucl Med 2024;65(2):313–319.
Download Paper | Download Slides
